RESEARCH TRIANGLE…Incara Pharmaceuticals Corp. officially becomes Aeolus Pharmaceuticals Inc. (OTC:AOLS) today (July 16).
The company’s stock symbol changes from ICRA to AOLS.
Also, Friday, the companys stock starts trading on a 10-1 reverse-split basis announced in June.
Aeolus is developing a new class of supercharged catalytic antioxidants that destroy the oxygen-derived free radicals implicated in development of many diseases. The company’s antioxidants have reduced tissue damage in animal studies of Lou Gehrig’s disease (ALS), stroke, cancr, and chonic obstructive pulmonary disease.
Aeolus filed an investigational new drug application for its lead compound, AEOL 10150. If approved, it will start Phase I clinical trials of the compound to treat ALS.